Iressa Promotion Halted; AstraZeneca To Highlight Tarceva Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Gefitinib fails to demonstrate a survival benefit in the Iressa Survival Evaluation in Lung cancer confirmatory trial. AstraZeneca will meet with FDA to determine whether accelerated approval licensure of Iressa will be withdrawn, CEO McKillop says.
You may also be interested in...
AstraZeneca Staking Its Growth On Oncology; Now It Needs Cancer Drugs
AstraZeneca has an ambitious agenda to become a leader in oncology. The company’s notably improved pipeline is broad, but winning will require AstraZeneca to come from behind to uncover the best combinations ahead of the competition.
AstraZeneca Gives Iressa Another Go In The EU
Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.
AstraZeneca Gives Iressa Another Go In The EU
Filing for marketing authorization in lung cancer comes three years after AstraZeneca initially withdrew its application.